During its more than 120 years history Richter has repeatedly demonstrated its ability to adapt to current trends and unmed medical needs, as well as its outstanding capability to continuously innovate.

An outstanding example of this are the drugs some of which were invented and developed by the founder of the company, and later by Richter’s talented R&D employees.

Mydocalm (spacticity), Cavinton (cerebrovascular diseases) or Vraylar/Reagila (antipsychotic), and fixed dose combinations such as Lisonorm are still our company’s leading products. In addition to his own developments Richter also succesfully licensed-in and launched products of different innovative companies in his traditional markets.

Richter has been enlarging its portfolio in the past 70 years with wide range of generic medicines, playing a leading role in this field in Central-Eastern Europe and CIS countries.

In 2018 the company management grouped the R&D and commercial activities into six pillars, and in 2023 merging the Traditional and Branded generic pillars in line with profit center concept established the General Medicines Business Unit.

The GenMed BU comprises of marketing, portfolio and project management, business development, and medical leadership working in close collaboration with other functions (R&D, IP, commercial, logistics) which play fundamental role in fulfilling GenMed development, sales and profit plans.

The GenMed portfolio consists of traditional Richter drugs, generic and licensed-in innovative products, covering mainly cardiometabolic diseases, CNS and rheumatology therapeutic areas. Our over-the-counter portfolio plays an important role in selected countries mainly in the cough&cold segment.

The GenMed BU may rely on three finished dosage development sites, located in Hungary, Poland and Romania, as well as GMP manufacturing sites beyond the above countries in Russia and in India (API manufacturing).

The development and manufacturing capabilities cover various solid, semi-solid and liquid formulations in different packaging materials under sterile and non-sterile conditions. 

Therapeutic Areas

  • Cardiometabolic diseases (cardiovascular, diabetes)
  • Central Nervous System
  • Rheumatology
  • Respiratory
  • Antinfectives
  • OTC products


Type of deals

  • License-in of generic products
  • License-in of value added products
  • License-in of innovative products (marketed and prior to MA approval)
  • License-in of OTC products
  • Divestiture of innovative products (tail-end patented products, off-patent products)



  • Central-Eastern Europe
  • Russia and countrties of former Soviet Union
  • Mongolia, Vietnam


What we offer

  • Over 1000 specialized sales representatives and key account managers in each country of the CEE and CIS region.
  • Large coverage of specialists and GPs.
  • Strong local back-office operation including marketing and products managers, medical liasons, regulatory and health technology activities.
  • Consistent headquarter support concerning portfolio management, regulatory, medical, marketing, strategic pricing and logistics.
  • Well-established relationship with local key opinion leaders, medical associations, health authorities (regulatory, payor), importers/distributors.

Mr Mihaly Majnar

Manager of Business Development, General Medicines Unit

M.Majnar @ richter.hu